ODDITY TECH LTD-CL A
ODDNASDAQTrading Snapshot
- Day Range
- $17.66 – $18.12
- 52-Week Range
- $9.25 – $63.24
- Volume
- $2.81B
- Avg Volume
- $1.90B
- Shares Outstanding
- 57.0M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $810M
- Last Q Revenue
- $181M
- P/E Ratio
- 58.7
- P/S Ratio
- 1.5x
- EPS (TTM)
- $0.32
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.9%
Why Investors Own ODD
- ✓High-growth profile — revenue up +17.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 51% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ODDITY TECH LTD-CL A
ODD
StockOtter · stockotter.spaceAbout ODDITY TECH LTD-CL A
Operating globally, Oddity Tech Ltd. and its affiliated companies function as a consumer technology enterprise. It delivers beauty and wellness merchandise, leveraging its proprietary PowerMatch technology. The firm's strategic focus is on developing and growing digitally native brands, aiming to revolutionize the traditionally brick-and-mortar beauty and wellness sectors. Its product portfolio features items for the face, complexion, eyes, brows, lips, and general skincare, marketed under the IL MAKIAGE label. Additionally, the SpoiledChild brand specializes in hair and skin care solutions. Founded in 2013, this corporation maintains its headquarters in Tel Aviv-Jaffa, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company's proprietary PD‑L1/4‑1B
ODDITY Tech Ltd (ODD) Shares Fall 5.1% -- What GF Score of 71 Tells Investors
On September 23, 2026, ODDITY Tech Ltd (ODD) shares fell 5.1% to $17.83, reflecting a significant drop in price performance over the last year, with a 52-week r
Earnings Estimates Moving Higher for Oddity Tech (ODD): Time to Buy?
Oddity Tech (ODD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Oddity Tech: Turnaround Potential And Discounted Debt Value Lever
ODD's turnaround could benefit from improving acquisition costs, even if profitability takes longer to recover than revenue. SpoiledChild is a nice, growing revenue base. And METHODIQ and Labs offer longer-term opportuni
Why Oddity Tech's Stock Skyrocketed 26.5% Today
Oddity Tech's second-quarter sales fell 25% to $181 million, just ahead of Wall Street's target. Earnings fell from $0.92 per share to $0.20, topping analyst estimates by a penny.
Oddity Tech Ltd. (ODD) Q2 2026 Earnings Call Transcript
Oddity Tech Ltd. (ODD) Q2 2026 Earnings Call Transcript